Overview
Avatrombopaq In Patients With Cirrhosis
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2022-06-01
2022-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Thrombocytopenia is a frequent issue in patients with cirrhosis undergoing various types of procedures (e.g. liver biopsy, endoscopy and minor surgical interventions). Thrombocytopenia < 50*10^9/L increases the risk of perioperative and postoperative bleedning and might prevent patients with cirrhosis to undergo important procedures. Doptelet is a small molecular trombopoetin agonist, which results in proliferation and differentiation of megakaryocytes in the bone marrow resulting in increased levels of thrombocytes. It is given orally as a pill and is used to increase platelet count in patients with severe thrombocytopenia (< 50*10^9/L) and cirrhosis and thus not to normalize platelet count. This study investigates the safety and efficacy of Doptelet in patients with cirrhosis and thrombocytopenia (< 50*10^9/L) undergoing minor procedures like Transjugular Adjusted Liver Biopsy (TJALB) and gastroscopy.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hvidovre University Hospital
Criteria
Inclusion Criteria:- Age: >17 years and ≤80 years
- ASA I-III
- Patients who read, understood and signed informed consent.
- Patients with a diagnosis of cirrhosis
- Thrombocytopenia <50*109
- The patient is scheduled for one of the following procedures: Transjugular Adjusted
Liver Biopsy (TJALB), gastroscopy or percutan paracentesis of ascites in the following
month.
Exclusion Criteria:
- Patients who do not speak and understand Danish.
- Patients who cannot cooperate within the trial.
- Patients who did not sign an informed consent regardless of the cause.
- Active drug abuse - to the discretion of the investigator.
- Thrombocytes >50*10^9
- Patients with hereditary trombolic diseases (e.g. Factor V Leiden, antithrombin
deficiency, protein S and C deficiency, prothrombin G202110A mutation).
- INR > 1,7
- Ongoing infection verified by blood culture, clinical examination, and acute phase
reactants (e.g. CRP)